Citi Pharma Limited, one of Pakistan’s well-known pharmaceutical companies, has announced plans to launch an initial public offering (IPO) for its subsidiary, Citi Veterinary Pharma Limited (CVPL). The company aims to raise between Rs 1 billion and Rs 2 billion through the IPO, which will help expand its operations in the veterinary medicine sector.
CVPL is focused on producing veterinary APIs (active pharmaceutical ingredients) and a variety of pharmaceutical products for animals. The subsidiary’s growth is part of Citi Pharma’s strategy to diversify its revenue sources beyond human medicines and strengthen its presence in the animal health market.
The company has appointed K-Trade Securities to manage and consult on the IPO process, ensuring proper compliance with regulatory requirements and transparency for potential investors. Citi Pharma hopes that the funds raised will support production expansion, research in animal health products, and improvements in distribution networks across Pakistan.
This initiative follows Citi Pharma’s recent entry into the real estate sector through a wholly owned REIT management subsidiary, highlighting the company’s broader plan to explore opportunities outside its traditional pharmaceutical business.
Experts say the veterinary market in Pakistan is growing steadily, with rising demand for animal health products from livestock, poultry, and pet owners.
With this IPO, Citi Pharma aims to strengthen its position in this sector while offering investors a chance to participate in a promising segment of the economy.
